Screener
Pacira BioSciences, Inc. PCRX Business Segments — Pre-Tax Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Changes in the fair value of contingent consideration | (2,277) | (2,675) |
| Legal settlement | — | 7,000 |
| Other (2) | 880 | 1,862 |
| Total operating expenses | 170,474 | 166,933 |
| Total other (expense) income, net | (1,904) | 6,716 |
| Income before income taxes | 4,998 | 8,706 |
| Income tax expense | (2,082) | (3,894) |
| Net income | $2,916 | $4,812 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s business segments — pre-tax income?
- Pacira BioSciences, Inc. (PCRX) reported business segments — pre-tax income of $5M in Q1 2026.
- How has Pacira BioSciences, Inc.'s business segments — pre-tax income changed year-over-year?
- Pacira BioSciences, Inc.'s business segments — pre-tax income decreased by 42.6% year-over-year, from $8.71M to $5M.
- What does business segments — pre-tax income mean?
- This metric measures the profitability of the reportable segment after accounting for all operating and non-operating expenses, but before the deduction of income tax provisions. It serves as a primary indicator of the segment's underlying operational performance and financial health. Investors use this to evaluate the segment's ability to generate earnings from its core business activities.
Ask your AI about Pacira BioSciences, Inc.'s business segments — pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude